AU2011324137B2 - A combination composition - Google Patents

A combination composition Download PDF

Info

Publication number
AU2011324137B2
AU2011324137B2 AU2011324137A AU2011324137A AU2011324137B2 AU 2011324137 B2 AU2011324137 B2 AU 2011324137B2 AU 2011324137 A AU2011324137 A AU 2011324137A AU 2011324137 A AU2011324137 A AU 2011324137A AU 2011324137 B2 AU2011324137 B2 AU 2011324137B2
Authority
AU
Australia
Prior art keywords
approximately
ibuprofen
paracetamol
combination
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2011324137A
Other languages
English (en)
Other versions
AU2011324137A1 (en
Inventor
Hartley Campbell Atkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFT Pharmaceuticals Ltd
Original Assignee
AFT Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011324137(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AFT Pharmaceuticals Ltd filed Critical AFT Pharmaceuticals Ltd
Publication of AU2011324137A1 publication Critical patent/AU2011324137A1/en
Application granted granted Critical
Publication of AU2011324137B2 publication Critical patent/AU2011324137B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2011324137A 2010-11-04 2011-10-26 A combination composition Active 2034-07-22 AU2011324137B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
NZ589011 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (2)

Publication Number Publication Date
AU2011324137A1 AU2011324137A1 (en) 2013-05-02
AU2011324137B2 true AU2011324137B2 (en) 2015-05-07

Family

ID=46024668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011324137A Active 2034-07-22 AU2011324137B2 (en) 2010-11-04 2011-10-26 A combination composition

Country Status (28)

Country Link
US (6) US20130225685A1 (enExample)
EP (1) EP2635269B1 (enExample)
JP (2) JP2013541583A (enExample)
KR (1) KR101900520B1 (enExample)
CN (2) CN107519159A (enExample)
AU (1) AU2011324137B2 (enExample)
BR (1) BR112013010829B8 (enExample)
CA (1) CA2814057C (enExample)
CL (1) CL2013001250A1 (enExample)
CO (1) CO6771406A2 (enExample)
CY (1) CY1123398T1 (enExample)
DK (1) DK2635269T3 (enExample)
ES (1) ES2742373T3 (enExample)
HR (1) HRP20191489T1 (enExample)
HU (1) HUE045442T2 (enExample)
LT (1) LT2635269T (enExample)
MX (2) MX367209B (enExample)
MY (1) MY160572A (enExample)
NZ (1) NZ609727A (enExample)
PH (2) PH12013500689A1 (enExample)
PL (1) PL2635269T3 (enExample)
PT (1) PT2635269T (enExample)
RS (1) RS59258B1 (enExample)
RU (2) RU2707089C2 (enExample)
SG (1) SG189319A1 (enExample)
SI (1) SI2635269T1 (enExample)
SM (1) SMT201900481T1 (enExample)
WO (1) WO2012060719A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005605A1 (en) * 2010-07-07 2012-01-12 Aft Pharmaceuticals Limited A combination composition comprising ibuprofen and paracetamol

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
JP5185488B2 (ja) * 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ，インコーポレーテッド ２−（４−イソブチルフェニル）プロピオン酸の医薬組成物
KR101113005B1 (ko) * 2003-03-21 2012-02-24 맥네일-피피씨, 인코포레이티드 비-스테로이드계 항염증성 약물 투여법
BRPI0512756A (pt) * 2004-07-07 2008-04-08 Aft Pharmaceuticals Ltd composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
ES2651444T3 (es) * 2006-10-20 2018-01-26 Johnson & Johnson Consumer Inc. Combinación de acetaminofeno con ibuprofeno para el tratamiento del dolor
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
TR201906742T4 (tr) * 2008-10-14 2019-05-21 Aft Pharmaceuticals Ltd Tıbbi bir ürün ve tedavi.
AU2010224063B2 (en) * 2009-03-12 2015-04-16 Cumberland Pharmaceuticals Inc Administration of intravenous ibuprofen
ES2742373T3 (es) 2010-11-04 2020-02-14 Aft Pharmaceuticals Ltd Una composición de combinación
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005605A1 (en) * 2010-07-07 2012-01-12 Aft Pharmaceuticals Limited A combination composition comprising ibuprofen and paracetamol

Also Published As

Publication number Publication date
US20160235695A1 (en) 2016-08-18
LT2635269T (lt) 2019-09-10
PH12013500689A1 (en) 2013-05-27
KR101900520B1 (ko) 2018-09-19
US11896567B2 (en) 2024-02-13
PT2635269T (pt) 2019-09-04
CA2814057A1 (en) 2012-05-10
MX2013005113A (es) 2013-06-03
EP2635269B1 (en) 2019-05-22
HUE045442T2 (hu) 2019-12-30
US20250134839A1 (en) 2025-05-01
MX367209B (es) 2019-07-22
JP6353577B2 (ja) 2018-07-04
PH12021550804A1 (en) 2022-02-14
ES2742373T3 (es) 2020-02-14
SMT201900481T1 (it) 2019-11-13
BR112013010829A2 (pt) 2016-08-16
US20190029982A1 (en) 2019-01-31
RU2707089C2 (ru) 2019-11-22
AU2011324137A1 (en) 2013-05-02
US20240207210A1 (en) 2024-06-27
CY1123398T1 (el) 2021-10-29
RU2015103107A (ru) 2015-06-20
CN107519159A (zh) 2017-12-29
US11446266B2 (en) 2022-09-20
PL2635269T3 (pl) 2019-11-29
RU2013123646A (ru) 2014-12-10
HRP20191489T1 (hr) 2019-11-15
BR112013010829B1 (pt) 2021-12-21
CL2013001250A1 (es) 2013-08-30
EP2635269A4 (en) 2014-09-17
RS59258B1 (sr) 2019-10-31
US20130225685A1 (en) 2013-08-29
JP2017132791A (ja) 2017-08-03
KR20140025314A (ko) 2014-03-04
CA2814057C (en) 2022-02-01
DK2635269T3 (da) 2019-08-26
NZ609727A (en) 2015-07-31
US12220392B2 (en) 2025-02-11
JP2013541583A (ja) 2013-11-14
SI2635269T1 (sl) 2019-10-30
CO6771406A2 (es) 2013-10-15
WO2012060719A1 (en) 2012-05-10
SG189319A1 (en) 2013-05-31
CN103298464A (zh) 2013-09-11
EP2635269A1 (en) 2013-09-11
US20230000805A1 (en) 2023-01-05
RU2015103107A3 (enExample) 2018-08-20
MY160572A (en) 2017-03-15
BR112013010829B8 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
US12220392B2 (en) Combination composition
JP7042531B2 (ja) デオキシコール酸を含む医薬組成物
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
CA2735834C (en) Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis
AU2011274652B2 (en) A combination composition comprising ibuprofen and paracetamol
CA2785360C (en) Treating critically ill patients with intravenous ibuprofen
CA2767971A1 (en) Treating patients with intravenous ibuprofen
US10265300B2 (en) Methods of treating seizure disorders
CN121868318A (zh) 联合治疗乳腺癌骨转移的药物
CA3032858A1 (en) Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity
WO2014150318A1 (en) Therapeutic agent for enhancing mitochondrial function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: MAXIGESIC IV PARACETAMOL AND IBUPROFEN (AS SODIUM DIHYDRATE)

Filing date: 20190722

NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 22 JUL 2019 TO 22 FEB 2020 IN WHICH TO REQUEST AN EXTENSION OF TERM - PHARMACEUTICAL HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST AN EXTENSION OF TERM - PHARMACEUTICAL HAS BEEN EXTENDED TO 22 FEB 2020

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 OCT 2020

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: MAXIGESIC IV PARACETAMOL AND IBUPROFEN (AS SODIUM DIHYDRATE)

Filing date: 20190722

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: MAXIGESIC IV PARACETAMOL AND IBUPROFEN (AS SODIUM DIHYDRATE)

Filing date: 20190722

Extension date: 20340722